- Details
- (Length of Discussion: 12 min) Alicia Morgans discusses with Mark Markowski details of the TRIUMPH trial, a single-arm, phase II trial, open-label using a PARP inhibitor rucaparib, in the absence of androgen deprivation therapy in men with metastatic hormone-naive prostate cancer. Biographies: Mark Christopher Markowski, MD., Ph.D., is a medical oncologist at the Kimmel Cancer Center at Sibley Mem...
|
- Details
- Todd Morgan shares the unique program that he and his GU team at the University of Michigan have implemented in an effort to gain a better understanding of the genetics and genomics involved with progression in prostate cancer. Biographies: Todd M. Morgan, M.D. is a urological surgeon specializing in the treatment of genitourinary malignancies and an Associate Professor of Urology and has been at...
|
- Details
- (Length of Discussion: 22 min) Alicia Morgans has a discussion with Dan George uncovering details about the IRONMAN Registry. The objective is to look globally at advanced prostate cancer, both with the metastatic and the castrate-resistant populations, seeking to understand patient outcomes and their experiences through this process. Biographies: Daniel George, MD Alicia Morgans, MD, MPH Read the...
|
- Details
- (Length of Discussion: 20 min) Alicia Morgans and David Penson discuss the relevance of Prostate Cancer Awareness Month and the importance of elevating the awareness for men and their respective caregivers about prostate cancer and other men's health issues and the need to be screened routinely for prostate cancer. Biographies: David F. Penson, MD, MPH, is the Paul V. Hamilton, M.D. and Virginia E...
|
- Details
- Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Biographies: Daniel Spratt, MD, Tenured Full Professor of Radiation Oncology and a leader in Prostate and Spine malignancies. Chief of the Genitourinary Radiotherapy Program, Associate Chair of Clinical Research, and the Laurie Snow Endowed Research Professor i...
|
- Details
- Alicia Morgans and Joaquin Mateo discuss mapping the genomic landscape of advanced prostate cancer, and the realization that many patients with advanced forms of prostate cancer have tumors with defects in the repair of DNA damage. And what we observed for the first time is actually that a drug like olaparib, a PARP inhibitor, that has been used in breast or ovarian cancer, were associated to thes...
|
- Details
- (Length of Presentation: 20 min) Neal Shore, MD, FACS interviews E. David Crawford on a forthcoming paper he authored titled, A ndrogen Receptor–Targeted Treatments for Prostate Cancer: 35 Years’ Progress with Anti-androgens . This paper takes the historical approach in reviewing the treatment of prostate cancer, where we started in the 60's, where we are today and where we hope to be in the futur...
|
- Details
- (Length of Discussion: 7 min) Charles Ryan and Carmel Pezaro have a conversation about Lutetium 177 PSMA based therapies in advanced prostate cancer. The experience she relates is unique to Australia leading to a difference in clinical options while presenting a potential conundrum with clinical trial designs. Biographies: Carmel Pezaro, MBChB, is a Senior Medical Oncologist and Senior Lecturer wo...
|
- Details
- (Length of Discussion: 12 min) Susan Halabi, the first biostatistician to become a fellow of ASCO, discusses recent data on overall survival in prostate cancer for black versus white men with Alicia Morgans and Charles Ryan. Susan discusses an analysis that showed an increase in overall survival in African American men vs Caucasian men, all of whom had metastatic castration-resistant prostate canc...
|
- Details
- (Length of Discussion: 16 min) An emerging expert in the field of genetics and prostate cancer, Heather Cheng speaks with Charles Ryan in a thought-provoking dialogue of genetic evaluation and counseling for patients with prostate cancer. They review a variety of the genes that are involved in both DNA repair as well as the Lynch Syndrome, wrapping up with a discussion about PARP Inhibitors. Biogr...
|
